

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2008

EQUITY INCOME FROM AFFILIATES (millions of dollars)

| | 4Q `08 | 4Q `07 | YTD 2008 | YTD 2007 |
|-------------------------|-----------------|-----------------|-------------------|-------------------|
| MERCK / SCHERING-PLOUGH | \$ 378.1 | \$ 537.7 | \$ 1,536.3 | \$ 1,830.8 |
| ASTRAZENECA LP | 266.8 | 211.8 | 598.4 | 820.1 |
| Other ⁽¹⁾ | 75.1 | 46.8 | 425.9 | 325.6 |
| TOTAL | \$ 720.0 | \$ 796.3 | \$ 2,560.6 | \$ 2,976.5 |

⁽¹⁾ Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & Johnson^oMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a "NET" basis.

| Merial | 4Q `08 | 4Q `07 | YTD 2008 | YTD 2007 |
|--------------------------------------|-----------------|-----------------|-------------------|-------------------|
| FRONTLINE, other fipronil | \$ 152.0 | \$ 167.2 | \$ 1,053.0 | \$ 1,033.3 |
| BIOLOGICALS | 208.8 | 202.1 | 789.7 | 674.9 |
| IVOMEK, HEARTGARD, other avermectins | 96.8 | 111.7 | 511.8 | 478.4 |
| Other Animal Health | 67.4 | 70.2 | 288.2 | 262.2 |
| TOTAL MERIAL SALES | \$ 525.0 | \$ 551.2 | \$ 2,642.7 | \$ 2,448.8 |

| Sanofi Pasteur-MSD | 4Q `08 | 4Q `07 | YTD 2008 | YTD 2007 |
|---------------------------------------|-----------------|-----------------|-------------------|-------------------|
| GARDASIL | \$ 171.2 | \$ 231.0 | \$ 865.3 | \$ 476.0 |
| VIRAL VACCINES | 24.4 | 21.8 | 105.1 | 86.8 |
| HEPATITIS VACCINES | 15.9 | 19.0 | 72.6 | 72.9 |
| Other Vaccines | 265.1 | 267.3 | 841.8 | 802.3 |
| TOTAL SANOFI PASTEUR-MSD SALES | \$ 476.6 | \$ 539.1 | \$ 1,884.8 | \$ 1,438.0 |

| Merck / Schering-Plough Collaboration | 4Q `08 | 4Q `07 | YTD 2008 | YTD 2007 |
|--|-------------------|-------------------|-------------------|-------------------|
| VYTORIN | \$ 549.5 | \$ 775.9 | \$ 2,360.0 | \$ 2,779.1 |
| ZETIA | 524.7 | 678.6 | 2,201.1 | 2,407.1 |
| TOTAL MERCK / SCHERING-PLOUGH SALES | \$ 1,074.2 | \$ 1,454.5 | \$ 4,561.1 | \$ 5,186.2 |

OTHER (INCOME) EXPENSE, NET (millions of dollars)

| | 4Q `08 | 4Q `07 | YTD 2008 | YTD 2007 |
|---------------------------|---------------|-----------------|---------------------|----------------|
| INTEREST INCOME | \$ (147.2) | \$ (200.2) | \$ (631.4) | \$ (741.1) |
| INTEREST EXPENSE | 56.7 | 87.1 | 251.3 | 384.3 |
| EXCHANGE LOSSES (GAINS) | 73.8 | (14.5) | 147.4 | (54.3) |
| MINORITY INTERESTS | 30.0 | 29.4 | 123.9 | 121.4 |
| Other, net ⁽¹⁾ | (10.1) | 665.6 | (2,085.4) | 335.9 |
| TOTAL | \$ 3.2 | \$ 567.4 | \$ (2,194.2) | \$ 46.2 |

⁽¹⁾ Other, net for full year 2008 primarily reflects a gain of \$2.2 billion related to a distribution from AstraZeneca LP. Other, net for the fourth quarter and full year 2007 reflects a civil governmental investigations charge of \$671.1 million.

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
FOURTH QUARTER
2008

NET PRODUCT SALES DETAIL (millions of dollars)

| PRODUCT | 4Q '08 vs. 4Q '07 | | | | | |
|-------------------------------------|-------------------|-------------|---------------|------------|------------------|---------------|
| | TOTAL % CHG | TOTAL \$ | U.S. % CHG | U.S. \$ | Foreign % CHG | Foreign \$ |
| COZAAR / HYZAAR | -1% | 881 | -3% | 319 | - | 562 |
| FOSAMAX | -60% | 318 | -85% | 77 | -12% | 241 |
| SINGULAIR | -3% | 1,122 | -11% | 709 | 15% | 413 |
| Vaccines: | | | | | | |
| GARDASIL | -16% | 286 | -19% | 216 | -2% | 69 |
| ROTATEQ | 9% | 162 | 4 | 148 | * | 14 |
| ZOSTAVAX | 89% | 162 | 89% | 162 | N/A | - |
| OTHER VIRAL VACCINES ⁽¹⁾ | -10% | 295 | -11% | 278 | 3% | 17 |
| HEPATITIS VACCINES ⁽²⁾ | -33% | 40 | -32% | 33 | -38% | 7 |
| OTHER VACCINES ⁽³⁾ | 5% | 132 | 8% | 97 | -2% | 35 |
| Other Reported Products: | | | | | | |
| ARCOXIA | -1% | 83 | N/A | - | -1% | 83 |
| CANCIDAS | 4% | 139 | 4% | 21 | 4% | 118 |
| COSOPT / TRUSOPT | -27% | 154 | -62% | 37 | 1% | 117 |
| CRIVAN / STOCRIN | -35% | 52 | -34% | 3 | -35% | 49 |
| EMEND | 16% | 71 | 23% | 47 | 6% | 24 |
| INVANZ | 29% | 68 | 35% | 38 | 21% | 30 |
| ISENTRESS | * | 130 | * | 71 | * | 59 |
| JANUVIA | 64% | 413 | 41% | 323 | * | 89 |
| JANUMET | * | 120 | * | 99 | * | 20 |
| MAXALT | 12% | 141 | 15% | 97 | 7% | 44 |
| PRIMAXIN | -13% | 169 | -24% | 39 | -10% | 130 |
| PROPECIA | -4% | 108 | -5% | 37 | -3% | 71 |
| PROSCAR | -14% | 72 | -46% | 2 | -12% | 69 |
| TIMOPTIC / TIMOPTIC XE | -3% | 31 | -9% | 2 | -3% | 29 |
| VASOTEC / VASERETIC | -32% | 85 | N/A | - | -32% | 85 |
| ZOCOR | -34% | 147 | -80% | 11 | -19% | 136 |
| ZOLINZA | 64% | 5 | 62% | 4 | * | - |

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ - Includes Recombivax and Vaqta

⁽³⁾ - Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE

| TOTAL PHARMACEUTICAL SALES | 4Q '08 \$ | % CHG | VOL | PX | FX |
|----------------------------|--------------|-------|-----|----|-----|
| | 6,032 | -3% | -4 | 1 | -1 |
| U.S. (\$ MM) | 3,396 | -9% | -12 | 4 | N/A |
| Foreign (\$ MM) | 2,636 | 5% | 10 | -3 | -2 |

MERCK & CO., INC.
OTHER FINANCIAL DISCLOSURES
DECEMBER YEAR-TO-DATE
2008

NET PRODUCT SALES DETAIL (millions of dollars)

| PRODUCT | DECEMBER YTD `08 vs. DECEMBER YTD `07 | | | | | |
|-------------------------------------|---------------------------------------|-------------|---------------|------------|------------------|---------------|
| | TOTAL % CHG | TOTAL \$ | U.S. % CHG | U.S. \$ | Foreign % CHG | Foreign \$ |
| COZAAR / HYZAAR | 6% | 3,558 | 1% | 1,247 | 9% | 2,311 |
| FOSAMAX | -49% | 1,553 | -75% | 498 | -1% | 1,054 |
| SINGULAIR | 2% | 4,337 | -6% | 2,825 | 19% | 1,511 |
| Vaccines: | | | | | | |
| GARDASIL | -5% | 1,403 | -13% | 1,041 | 26% | 362 |
| ROTATEQ | 27% | 665 | 24% | 618 | 83% | 46 |
| ZOSTAVAX | 32% | 312 | 32% | 312 | N/A | - |
| OTHER VIRAL VACCINES ⁽¹⁾ | -6% | 1,268 | -8% | 1,175 | 38% | 94 |
| HEPATITIS VACCINES ⁽²⁾ | -47% | 148 | -52% | 112 | -21% | 36 |
| OTHER VACCINES ⁽³⁾ | -13% | 355 | -32% | 206 | 38% | 149 |
| Other Reported Products: | | | | | | |
| ARCOXIA | 15% | 377 | N/A | - | 15% | 377 |
| CANCIDAS | 11% | 596 | -21% | 100 | 21% | 496 |
| COSOPT / TRUSOPT | -1% | 781 | -17% | 291 | 12% | 491 |
| CRIVAN / STOCRIN | -11% | 275 | -36% | 13 | -10% | 262 |
| EMEND | 29% | 264 | 24% | 172 | 41% | 92 |
| INVANZ | 39% | 265 | 32% | 138 | 48% | 127 |
| ISENTRESS | * | 361 | * | 202 | * | 159 |
| JANUVIA | * | 1,397 | 79% | 1,110 | * | 287 |
| JANUMET | * | 351 | * | 308 | * | 43 |
| MAXALT | 13% | 529 | 13% | 354 | 14% | 175 |
| PRIMAXIN | - | 760 | -22% | 163 | 8% | 598 |
| PROPECIA | 6% | 429 | -1% | 151 | 10% | 278 |
| PROSCAR | -21% | 324 | -79% | 12 | -12% | 311 |
| TIMOPTIC / TIMOPTIC XE | 2% | 122 | -10% | 7 | 2% | 115 |
| VASOTEC / VASERETIC | -28% | 357 | N/A | - | -28% | 357 |
| ZOCOR | -25% | 660 | -59% | 75 | -16% | 585 |
| ZOLINZA | 40% | 15 | 34% | 14 | * | 1 |

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ - Includes Recombivax and Vaqta

⁽³⁾ - Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE

| | FY '08 | % CHG | VOL | PX | FX |
|-----------------------------------|-----------|-------|-----|----|-----|
| TOTAL PHARMACEUTICAL SALES | \$ 23,850 | -1% | -4 | = | 3 |
| U.S. (\$ MM) | 13,370 | -9% | -11 | 2 | N/A |
| Foreign (\$ MM) | 10,480 | 10% | 7 | -4 | 7 |